Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
New York, New YorkAges 18 years+ - NCT07659782RecruitingPhase 2
Study of VS-7375 for KRAS G12D lung cancer
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
New York, New YorkAges 18 years+ - NCT07743190RecruitingPhase 2
Lighter chemo for early-stage triple-negative breast cancer with high immune cells
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Syracuse, New YorkAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of raludotatug deruxtecan for ovarian cancer
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
New York, New YorkAges 18 years+ - NCT07659795RecruitingPhase 2
Study of VS-7375 for KRAS G12D colorectal cancer
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
New York, New YorkAges 18 years+ - NCT06712316RecruitingPhase 2/Phase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
Poughkeepsie, New YorkAges 18 years+ - NCT04245683Recruiting
Testing non-surgical treatment for newly diagnosed rectal cancer
This study looks at whether it’s practical and safe to treat certain rectal cancers without surgery. You may be offered non-surgical (“neoadjuvant”) treatment and close follow-up to see how well it works in a rural setting.
Cooperstown, New YorkAges 18 years+ - NCT05076942RecruitingPhase 2
Study of sentinel lymph nodes in vulvar cancer
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
New York, New YorkAges 18 years+ - NCT06084416RecruitingPhase 1
Pill study for advanced ovarian cancer that resists chemo
This trial tests an experimental drug called sovilnesib (taken as a pill) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemo. The goal is to see if this drug can shrink or slow the cancer.
Buffalo, New YorkAges 18 years+ - NCT07871435RecruitingPhase 1/Phase 2
Investigational combo for advanced prostate cancer
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT07128199RecruitingPhase 3
Zipalertinib after surgery for early-stage lung cancer with uncommon EGFR mutations
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
Commack, New YorkAges 18 years+ - NCT06343077RecruitingPhase 2
Hiltonol injection for prostate cancer on active surveillance
This trial tests a drug called Hiltonol (Poly-ICLC) given directly into the prostate tumor along with an injection under the skin. It is for men with low-risk prostate cancer who are on active surveillance, to see if the drug can slow or stop the cancer from growing.
New York, New YorkAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
West Islip, New YorkAges 18 years+ - NCT07843940RecruitingPhase 1/Phase 2
Two study drugs for extensive-stage small cell lung cancer
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT07801664RecruitingPhase 2
Short course hormone therapy for prostate cancer
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
New York, New YorkAges 18 years+ - NCT07802353Recruiting
Focused radiation after brain tumor surgery
This study tests a type of radiation called stereotactic radiosurgery (SRS) given right after surgery to remove a brain tumor. The goal is to see if it helps control the tumor with fewer side effects.
Rockville Centre, New YorkAges 18 years+ - NCT07767500Recruiting
MRI-guided radiation therapy for early-stage kidney cancer
This trial tests a new way to deliver radiation to kidney tumors using MRI guidance. It aims to treat early-stage kidney cancer while sparing healthy tissue, and may be an option for people who cannot have surgery or prefer not to.
New York, New YorkAges 18 years+ - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Syracuse, New YorkAges 18 years+ - NCT05462496RecruitingPhase 2
Pembrolizumab plus gut microbiome changes after pancreatic chemo
This Phase 2 study tests whether changing the gut microbiome (the gut’s helpful bacteria) and giving pembrolizumab after chemotherapy can improve outcomes for people with operable pancreatic cancer. It aims to see if this approach can boost the immune system after standard treatment and help reduce cancer returning.
New York, New YorkAges 19 years+ - NCT07701941RecruitingPhase 1/Phase 2
Combination treatment for advanced breast cancer
This trial tests two targeted drugs together for people with advanced breast cancer that is hormone receptor positive and has low levels of a protein called HER2. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
New York, New YorkAges 18 years+ - NCT07673731Enrolling by invitation
Managing cancer distress through survivorship care
This study tests a program to help cancer patients manage distress during treatment. You may qualify if you are starting a new therapy and feeling distressed.
Schenectady, New YorkAges 18 years+ - NCT06579417Recruiting
Testing a faster MRI for prostate cancer detection
This trial is testing a new, faster type of MRI scan (called biparametric MRI) to see if it can detect prostate cancer as well as the standard scan. It may help you avoid a longer scan and possibly reduce the need for contrast dye.
New York, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 6 studies
- NYU Langone Health · 5 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Memorial Sloan Kettering Commack · 2 studies
- Memorial Sloan Kettering Westchester · 2 studies
- State University of New York Upstate Medical University · 2 studies
- Bassett Healthcare Network
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.